EQRx resets to focus on clinically differentiated medicines:
EQRx resets to focus on clinically differentiated medicines: Prioritizing development of lerociclib (CDK 4/6 inhibitor); initiated Phase III trial in first-line advanced endometrial cancer; enrollment in Phase II trial in first- and second-line advanced breast cancer near completion, providing a foundation for future combination development opportunities.
Seeking commercialization partnerships for aumolertinib (third-generation EGFR inhibitor). Terminating license agreements for sugemalimab (anti-PD-L1 antibody), nofazinlimab (anti-PD-1 antibody) and EQ121 (JAK-1 inhibitor).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins